Inotiv, Inc. & Synexa Life Sciences Sign Letter of Intent to Establish Center of Excellence for Biotherapeutics & Biomarkers

Inotiv, Inc. and Synexa Life Sciences recently announced they intend to form a collaboration that will accelerate Inotiv’s development of biomarkers essential to the understanding of safety and efficacy of novel biotherapeutics, enhancing the company’s core preclinical discovery and safety assessment services.

This collaboration will provide Synexa with further international expansion of its clinical biomarker and bioanalytical offering. Under this commercial collaboration, Synexa will support Inotiv in developing and delivering comprehensive GLP biomarker and biotherapeutics bioanalytical services, and Synexa will lease laboratory space at Inotiv’s Rockville, MD, site to establish US operations.

“The evolving complexity of novel biotherapeutics, such as cell and gene therapies, requires laboratories with real expertise to develop and validate methods and to perform analysis in the preclinical and clinical fields to satisfy the scrutiny of international regulatory authorities throughout the entirety of the drug development process,” said Kenneth Swart, PhD, Inotiv’s Senior Vice President of Bioanalytical and Biotherapeutic Sciences. “The complementary service offerings of Inotiv and Synexa will allow us to combine deep expertise and scientific capabilities to build a comprehensive bioanalytical and biomarker solution in the field of biotherapeutics with a priority to support our clients’ molecules from discovery into regulated preclinical (GLP) analysis.”

“We are very excited to combine forces with Inotiv in such a promising new collaboration,” said Synexa CEO Paul O’Riordan. “Our clients need new solutions in an ever more complex drug development environment, and a seamless transition from the preclinical to the clinical phase will help reduce risk and accelerate successful outcomes. Consistent and high-quality biomarker and bioanalytical solutions are key to bridging that gap. We look forward to working with Inotiv to bring this innovative idea to market.”

The expected benefits of the collaboration include:

• Simplifying the outsourcing of preclinical and clinical regulated biotherapeutics and biomarker services.
• Building preferred provider partnerships with fast-growing biopharmaceutical companies, focusing on a pipeline/follow-the-molecule approach.
• Combining deep scientific expertise across the DNA-RNA-Protein-Cell-Tissue continuum.
• Delivering potential cost and revenue synergies through SG&A expense savings and cross-selling existing clients across a broader platform of services.

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. For more information, visit https://www.inotivco.com/.

Synexa Life Sciences is a global leader the application of biomarker and bioanalytical science to help biopharma clients meet their clinical development targets. Founded in 2003 as an early pioneer in the biomarker field, Synexa specializes in the development, validation and delivery of a wide range of complex and custom-designed assays, based on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Headquartered at the Leiden Bio Science Park, The Netherlands, Synexa has GCLP accredited laboratories in London, Berlin and Cape Town. For more information, visit www.synexagroup.com.